HAS Healthcare Advanced Synthesis, founded in 1984, is an independent entity within the Helsinn Group and located in Biasca, Switzerland. They specialize in cancer-supporting healthcare and cancer therapeutics. The company focuses on the in- and out-licensing of pharmaceuticals, identifying innovative novel chemical entities (NCEs) and overseeing their development and manufacturing. Over the past three decades, they have built and successfully transferred more than 150 projects, conducting a wide range of CMC and regulatory activities in addition to GMP manufacturing, clinical trial material production, and commercial launch supply. In 2025, HAS Healthcare Advanced Synthesis acquired Cerbios, forming a HAS Group of CDMOs in a highly complementary arrangement.